Skip to content

National Health Investors NHI Gains on forward equity sales agreements, net

Gains on forward equity sales agreements, net at other companies

Blue Owl Technology Finance Corp. logo
Blue Owl Technology Finance Corp.OTF
$100.67M+5,350%
Lincoln National logo
Lincoln NationalLNC
$2M+140%
Blue Owl Capital logo
Blue Owl CapitalOBDC
-$84.91M+44.1%
Golub Capital logo
Golub CapitalGBDC
-$1.45M+91.4%
Vulcan Materials Company logo
Vulcan Materials CompanyVMC
$0-100%
MGIC Investment Corp. logo
MGIC Investment Corp.MTG
-$169K-123%

Other financials

Income statement

See full
Revenue$115.1M+28.9%
Net income$40.1M+17.4%
EPS (diluted)$0.82+10.8%

Balance sheet

See full
Cash & equivalents$24.9M-81.8%
Total debt$1.4B+8.4%
Total equity$1.5B+6.2%
Total assets$2.9B+3.8%

Cash flow

See full
Operating cash flow$53.4M+15.0%

Valuation

See full
Market cap$3.54B+16.1%

Profitability

See full
Operating margin50.1%
Net margin36.9%-4.3pp
FCF margin70.1%

Returns & leverage

See full
Return on equity10.1%-0.5pp
Debt / equity0.9×0.0×

Where this comes from

Reported directly by National Health Investors in its filing.

Tagged under the XBRL concept nhi:NonCashGainOnEquityForward.

The official record: National Health Investors’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about National Health Investors's gains on forward equity sales agreements, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is National Health Investors's gains on forward equity sales agreements, net?
National Health Investors (NHI) reported gains on forward equity sales agreements, net of $0 in Q4 2025.
How has National Health Investors's gains on forward equity sales agreements, net changed year-over-year?
National Health Investors's gains on forward equity sales agreements, net increased by 100.0% year-over-year, from -$1.57M to $0.
What does gains on forward equity sales agreements, net mean?
Represents non-cash gains recognized from forward equity sales agreements used to manage capital structure and equity issuance timing. This metric adjusts net income to reflect the impact of derivative or forward contract valuations that do not involve immediate cash inflows. It is essential for understanding how financial instruments impact reported earnings without affecting current operating cash flow.